Beacon Equity issues Trading Overview for Advanced Cell Technology Inc.
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, October 14, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring biotechnology company Advanced Cell Technology Inc. (OTCBB: ACTC).
The investment report on Advanced Cell Technology Inc. (OTCBB: ACTC) should be of particular interest to other biotechnology companies: Genzyme Corp. (Nasdaq: GENZ), Geron Corp. (Nasdaq: GERN) and StemCells Inc. (Nasdaq: STEM).
It is available at: http://www.beaconequity.com/i/ACTC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Advanced Cell Technology Inc. (ACTC) engages in the research and development of specialized stem-cell technologies for the treatment of various diseases or conditions. The Company's proprietary methods are intended to bring novel approaches in the area of regenerative medicine.
In the report, the analyst notes:
“The Company believes the Retinal Pigment Epithelium (RPE) program will yield new treatments for the eye disease macular degeneration related to aging, with the first therapy for the treatment of Stargardt's disease. The Company's collaboration with Casey Eye Institute at OHSU has shown positive results supporting efficacy and safety for the treatment of retinal diseases, and intends to file an Investigational New Drug application with the Food and Drug Administration (FDA) by year-end.
“On October 6, the Company announced that it is up-to-date on its financial statements and filings, and now trades on the OTCBB. The move from the Pink Sheets increases the Company's potential investor base and ability to raise additional capital.”
To read the entire report visit: http://www.beaconequity.com/i/ACTC
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The investment report on Advanced Cell Technology Inc. (OTCBB: ACTC) should be of particular interest to other biotechnology companies: Genzyme Corp. (Nasdaq: GENZ), Geron Corp. (Nasdaq: GERN) and StemCells Inc. (Nasdaq: STEM).
It is available at: http://www.beaconequity.com/i/ACTC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Advanced Cell Technology Inc. (ACTC) engages in the research and development of specialized stem-cell technologies for the treatment of various diseases or conditions. The Company's proprietary methods are intended to bring novel approaches in the area of regenerative medicine.
In the report, the analyst notes:
“The Company believes the Retinal Pigment Epithelium (RPE) program will yield new treatments for the eye disease macular degeneration related to aging, with the first therapy for the treatment of Stargardt's disease. The Company's collaboration with Casey Eye Institute at OHSU has shown positive results supporting efficacy and safety for the treatment of retinal diseases, and intends to file an Investigational New Drug application with the Food and Drug Administration (FDA) by year-end.
“On October 6, the Company announced that it is up-to-date on its financial statements and filings, and now trades on the OTCBB. The move from the Pink Sheets increases the Company's potential investor base and ability to raise additional capital.”
To read the entire report visit: http://www.beaconequity.com/i/ACTC
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |